Yıl: 2021 Cilt: 36 Sayı: 1 Sayfa Aralığı: 30 - 35 Metin Dili: İngilizce DOI: 10.5222/MMJ.2021.43066 İndeks Tarihi: 05-06-2021

The Comparison Between Non-High Risk Patients with and Without Cancer Diagnosed with Pulmonary Embolism

Öz:
Objective: This study aimed to compare the pulmonary embolism (PE) location and clot burden on computed tomography pulmonary angiography (CTPA), the degree of right ventricular dysfunction (RVD), D-dimer, and cardiac troponin I (cTnI) levels, and the presence of a lower extremity deep venous thrombosis (DVT) in patients with and without cancer diagnosed with a non high risk pulmonary embolism (PE).Method: We calculated Miller score for each patient for clot burden. The location of PE was also evaluated at CTPA. D-dimer and cardiac cTnI levels were measured. Patients had echocardiography for RVD and lower extremity color flow Doppler ultrasonography for DVT.Results: The study included 71 patients with PE. The patients were divided into two groups according to the presence of cancer. There was no statistically significant difference for D-dimer levels (P=0.15), PE location (p=0.67), clot burden (P=0.34), RVD (P=0.28) and DVT (P=0.33) between groups (P=0.15). Cancer patients diagnosed as PE had statistically significantly higher levels of cTnI than those who were diagnosed as PE without cancer (P=0.03).Conclusion: There was no significant difference between patients diagnosed as PE with and without cancer in terms of D-dimer levels, clot burden and emboli location, RVD and DVT. cTnI levels were higher in non-high risk PE patients with cancer than these patients without cancer.
Anahtar Kelime:

Kanseri Olan ve Olmayan Yüksek Riskli Olmayan Pulmoner Emboli Hastalarının Karşılaştırılması

Öz:
Amaç: Bu çalışma, kanseri olan ve olmayan yüksek riskli olmayan pulmoner emboli (PE) hastalarında pulmoner bilgisayarlı tomografik anjiyografide (PBTA) PE lokalizasyonu, trombüs yükü, sağ ventrikül disfonksiyonu (SVD), serum D-dimer, serum kardiyak troponin I (kTnI) ve alt ekstremite derin ven trombozu (DVT) varlığının karşılaştırılmasını amaçlamıştır. Yöntem: Her hasta için trombüs yükü Miller Skoru ile hesaplandı. PE yeri PTBA’da değerlendirildi. Serum D-dimer, kTnI düzeyleri ölçüldü. Hastalara SVD için ekokardiyografi ve DVT için alt ekstremite renkli mod doppler ultrasonografi yapıldı. Bulgular: PE tanılı yetmiş bir hasta çalışmaya alındı. Hastalar kanser varlığına göre iki gruba ayrıldı. İki grup arasında D-dimer düzeyleri (p=0,15), PE yeri (p=0,67), trombüs yükü (p=0,34), SVD (p=0,28) ve DVT (p=0,33) yönünden istatistiki anlamlı bir fark saptanmadı. Kanseri olan ve PE tanısı konulan hastalar, kanser tanısı olmayanlara göre istatistiksel olarak anlamlı derecede daha yüksek kTnI düzeylerine sahipti (p=0,03). Sonuç: Kanseri olan ve olmayan PE tanısı konulan hastalar arasında D-dimer, trombüs yükü, emboli yerleşimi, SVD ve DVT varlığı açısından fark saptanmadı. Kanseri olan yüksek riskli olmayan PE hastalarında kTnI düzeyleri, kanseri olmayan yüksek riskli olmayan PE hastalarından daha yüksekti.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Konstantinides SV, Torbicki A, Agnelli G, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014;35:3033-69. [CrossRef]
  • 2. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160:809-15. [CrossRef]
  • 3. Sanchez O, Trinquart L, Caille V, et al. Prognostic factors for pulmonary embolism: the prep study, a prospective multicenter cohort study. Am J Respir Crit Care Med. 2010;181:168-73. [CrossRef]
  • 4. Trujillo-Santos J, Nieto JA, Tiberio G, et al. Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Thromb Haemost. 2008;100:435-9. [CrossRef]
  • 5. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 1999;78:285-91. [CrossRef]
  • 6. Patel A, Kassar K, Veer M, Doyle M, Kanwar M. Clot burden serves as an effective predictor of 30 day mortality in patients with acute pulmonary embolism. JACC. 2018;71:A1933. [CrossRef]
  • 7. Vedovati MC, Germini F, Agnelli G, Becattini C. Prognostic role of embolic burden assessed at computed tomography angiography in patients with acute pulmonary embolism: systematic review and meta-analysis. J Thromb Haemost. 2013;11:2092-102. [CrossRef]
  • 8. Bankier AA, Janata K, Fleischmann D, et al. Severity assessment of acute pulmonary embolism with spiral CT: evaluation of two modified angiographic scores and comparison with clinical data. J Thorac Imaging. 1997;12:150-8. [CrossRef]
  • 9. Becattini C, Vedovati MC, Agnelli G. Prognostic value of troponins in acute pulmonary embolism: a meta-analysis. Circulation. 2007;116:427-33. [CrossRef]
  • 10. Kilinc G, Dogan OT, Berk S, Epozturk K, Ozsahin SL, Akkurt I. Significance of serum cardiac troponin I levels in pulmonary embolism. J Thorac Dis. 2012;4:588-93. [CrossRef]
  • 11. Lega JC, Lacasse Y, Lakhal L, Provencher S. Natriuretic peptides and troponins in pulmonary embolism: a meta-analysis. Thorax. 2009;64:869-75. [CrossRef]
  • 12. Jiménez D, Díaz G, Molina J, et al. Troponin I and risk stratification of patients with acute nonmassive pulmonary embolism. Eur Respir J. 2008;31:847-53. [CrossRef]
  • 13. Keller K, Geyer M, Beule J, Coldewey M, Balzer JO, Dippold W. Impact of cancer on the effectiveness of cardiac Troponin I to predict right ventricular dysfunction in acute pulmonary embolism. Thorac Cancer. 2015;6:584-8. [CrossRef]
  • 14. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. 1999;353:1386-9. [CrossRef]
  • 15. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5:632-4. [CrossRef]
  • 16. Lyman GH. Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. Cancer. 2011;117:1334-49. [CrossRef]
  • 17. Prandoni P, Lensing AWA, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100:3484-8. [CrossRef]
  • 18. Righini M, Le Gal G, De Lucia S, et al. Clinical usefulness of D-dimer testing in cancer patients with suspected pulmonary embolism. Thromb Haemost. 2006;95:715-9. [CrossRef]
  • 19. Ay C, Dunkler D, Pirker R, et al. High D-dimer levels are associated with poor prognosis in cancer patients. Haematologica. 2012;97:1158-64. [CrossRef]
  • 20. Furlan A, Aghayev A, Chang CCH, et al. Short-term mortality in acute pulmonary embolism: clot burden and signs of right heart dysfunction at CT pulmonary angiography. Radiology. 2012;265:283-93. [CrossRef]
  • 21. Ribeiro A, Lindmarker P, Juhlin-Dannfelt A, Johnsson H, Jorfeldt L. Echocardiography Doppler in pulmonary embolism: right ventricular dysfunction as a predictor of mortality rate. Am Heart J. 1997;134:479-87. [CrossRef]
  • 22. ten Wolde M, Söhne M, Quak E, Mac Gillavry MR, Büller HR. Prognostic value of echocardiographically assessed right ventricular dysfunction in patients with pulmonary embolism. Arch Intern Med. 2004;164:1685-9. [CrossRef]
  • 23. Kucher N, Rossi E, De Rosa M, Goldhaber SZ. Prognostic role of echocardiography among patients with acute pulmonary embolism and a systolic arterial pressure of 90 mm Hg or higher. Arch Intern Med. 2005;165:1777-81. [CrossRef]
  • 24. Torbicki A, Perrier A, Konstantinides S, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J. 2008;29:2276-315. [CrossRef]
  • 25. Blom JW, Vanderschoot JPM, Oostindiër MJ, Osanto S, van der Meer FJM, Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost. 2006;4:529-35. [CrossRef]
  • 26. Girard P, Sanchez O, Leroyer C, et al. Deep venous thrombosis in patients with acute pulmonary embolism: prevalence, risk factors, and clinical significance. Chest. 2005;128:1593-600. [CrossRef]
  • 27. Stein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med. 2006;119:60-8. [CrossRef]
APA Caliskan T, Türkoğlu Ö, Canoğlu K, Ayten O, Şaylan B, Okutan O, kartaloglu z (2021). The Comparison Between Non-High Risk Patients with and Without Cancer Diagnosed with Pulmonary Embolism. , 30 - 35. 10.5222/MMJ.2021.43066
Chicago Caliskan Tayfun,Türkoğlu Özlem,Canoğlu Kadir,Ayten Omer,Şaylan Bengü,Okutan Oguzhan,kartaloglu zafer The Comparison Between Non-High Risk Patients with and Without Cancer Diagnosed with Pulmonary Embolism. (2021): 30 - 35. 10.5222/MMJ.2021.43066
MLA Caliskan Tayfun,Türkoğlu Özlem,Canoğlu Kadir,Ayten Omer,Şaylan Bengü,Okutan Oguzhan,kartaloglu zafer The Comparison Between Non-High Risk Patients with and Without Cancer Diagnosed with Pulmonary Embolism. , 2021, ss.30 - 35. 10.5222/MMJ.2021.43066
AMA Caliskan T,Türkoğlu Ö,Canoğlu K,Ayten O,Şaylan B,Okutan O,kartaloglu z The Comparison Between Non-High Risk Patients with and Without Cancer Diagnosed with Pulmonary Embolism. . 2021; 30 - 35. 10.5222/MMJ.2021.43066
Vancouver Caliskan T,Türkoğlu Ö,Canoğlu K,Ayten O,Şaylan B,Okutan O,kartaloglu z The Comparison Between Non-High Risk Patients with and Without Cancer Diagnosed with Pulmonary Embolism. . 2021; 30 - 35. 10.5222/MMJ.2021.43066
IEEE Caliskan T,Türkoğlu Ö,Canoğlu K,Ayten O,Şaylan B,Okutan O,kartaloglu z "The Comparison Between Non-High Risk Patients with and Without Cancer Diagnosed with Pulmonary Embolism." , ss.30 - 35, 2021. 10.5222/MMJ.2021.43066
ISNAD Caliskan, Tayfun vd. "The Comparison Between Non-High Risk Patients with and Without Cancer Diagnosed with Pulmonary Embolism". (2021), 30-35. https://doi.org/10.5222/MMJ.2021.43066
APA Caliskan T, Türkoğlu Ö, Canoğlu K, Ayten O, Şaylan B, Okutan O, kartaloglu z (2021). The Comparison Between Non-High Risk Patients with and Without Cancer Diagnosed with Pulmonary Embolism. Medeniyet Medical Journal, 36(1), 30 - 35. 10.5222/MMJ.2021.43066
Chicago Caliskan Tayfun,Türkoğlu Özlem,Canoğlu Kadir,Ayten Omer,Şaylan Bengü,Okutan Oguzhan,kartaloglu zafer The Comparison Between Non-High Risk Patients with and Without Cancer Diagnosed with Pulmonary Embolism. Medeniyet Medical Journal 36, no.1 (2021): 30 - 35. 10.5222/MMJ.2021.43066
MLA Caliskan Tayfun,Türkoğlu Özlem,Canoğlu Kadir,Ayten Omer,Şaylan Bengü,Okutan Oguzhan,kartaloglu zafer The Comparison Between Non-High Risk Patients with and Without Cancer Diagnosed with Pulmonary Embolism. Medeniyet Medical Journal, vol.36, no.1, 2021, ss.30 - 35. 10.5222/MMJ.2021.43066
AMA Caliskan T,Türkoğlu Ö,Canoğlu K,Ayten O,Şaylan B,Okutan O,kartaloglu z The Comparison Between Non-High Risk Patients with and Without Cancer Diagnosed with Pulmonary Embolism. Medeniyet Medical Journal. 2021; 36(1): 30 - 35. 10.5222/MMJ.2021.43066
Vancouver Caliskan T,Türkoğlu Ö,Canoğlu K,Ayten O,Şaylan B,Okutan O,kartaloglu z The Comparison Between Non-High Risk Patients with and Without Cancer Diagnosed with Pulmonary Embolism. Medeniyet Medical Journal. 2021; 36(1): 30 - 35. 10.5222/MMJ.2021.43066
IEEE Caliskan T,Türkoğlu Ö,Canoğlu K,Ayten O,Şaylan B,Okutan O,kartaloglu z "The Comparison Between Non-High Risk Patients with and Without Cancer Diagnosed with Pulmonary Embolism." Medeniyet Medical Journal, 36, ss.30 - 35, 2021. 10.5222/MMJ.2021.43066
ISNAD Caliskan, Tayfun vd. "The Comparison Between Non-High Risk Patients with and Without Cancer Diagnosed with Pulmonary Embolism". Medeniyet Medical Journal 36/1 (2021), 30-35. https://doi.org/10.5222/MMJ.2021.43066